Advancing Early Diagnosis and Management of Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF): A Path to Better Patient Outcomes

Speaker
Deborah Assayag, MD, FRCPC
McGill University, Montreal, QC

Moderator
Colin Adams, MD, FRCPC
KW Cardiopulmonary Services, Waterloo, ON

Session Description

Discussing Importance of early diagnostic, setting patient expectation for therapy and practical tips for managing side effects in a community setting.

Learning Objectives

At the end of this presentation, attendees will be able to:

• Recognize the importance of early diagnosis of ILD /IPF
• Understand the benefits and limitations of ILD/IPF medications
• Develop a practical approach to management of ILD/IPF medications and their side effects

CanMEDS Roles: Collaborator, Communicator, Health Advocate, Leader, Medical Expert

This session is co-developed by the CTS and Boehringer-Ingelheim and is planned to achieve scientific integrity, objectivity and balance.